SCHEMBL3077841

SCHEMBL3077841

[2H]C([2H])(Cl)c1ccc(C(=O)Cl)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
ALDH1A1 P00352 6/20 0.42
KMT2A Q03164 2/20 0.37
GSK3B P49841 1/20 0.35
POLB P06746 3/20 0.35
MAPT P10636 3/20 0.35
RAB9A P51151 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
THRB P10828 2/20 0.34
THRA P10827 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
NPC1 O15118 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
GAA P10253 1/20 0.33
NR4A1 P22736 1/20 0.33
APEX1 P27695 1/20 0.33
APOBEC3A P31941 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL186794 0.81 CA1 (0.64) CA1CA2ALDH1A1KMT2AGSK3B
Methylene Chloride SCHEMBL29223376 0.80 ALDH1A1 (0.52) CA1CA2ALDH1A1GSK3BMAPT
SCHEMBL7132233 0.78 HDAC1 (0.47) CA1CA2ALDH1A1KMT2APOLB
SCHEMBL1290930 0.78 KMT2A (0.58) CA1CA2ALDH1A1KMT2ASMN1; SMN2
SCHEMBL3962189 0.77 CA1 (0.43) CA1CA2ALDH1A1KMT2APOLB
SCHEMBL68148 0.77 ALDH1A1 (0.59) CA1CA2ALDH1A1MAPTCES2
SCHEMBL20587670 0.77 ALDH1A1 (0.59) CA1CA2ALDH1A1MAPTCES2
SCHEMBL13138677 0.77 KMT2A (0.41) CA1CA2ALDH1A1KMT2AMAPT
SCHEMBL91167 0.76 PRSS1 (0.48) CA1CA2ALDH1A1KMT2ARAB9A
SCHEMBL18892653 0.74 ALDH1A1 (0.43) CA1CA2ALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130121963-A1 N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES CONCERT PHARMACEUTICALS INC. (US) 2013-05-16 US disclosed
US-20100221221-A1 N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES CONCERT PHARMACEUTICALS INC. (US) 2010-09-02 US disclosed
WO-2010019557-A1 N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES CONCERT PHARMACEUTICALS INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130121963-A1 N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES NME2, NME1, ABL1 CA1 4884/4885CA2 4403/4885ALDH1A1 3768/4885
US-20100221221-A1 N-PHENYL-2-PYRIMIDINEAMINE DERIVATIVES NME2, NME1, ABL1 CA1 4884/4885CA2 4403/4885ALDH1A1 3768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.